Physician profile
Jada Kitchen
NPI 1811181936
$2,552.11
in general payments reported to CMS, 2019-2025
23 companies · $561 in 2025
The $561 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $159 · 2022: $390 · 2023: $498 · 2024: $944 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,937 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,936.84 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $464.59 | 2022-2025 | |
| Novo Nordisk INC | $391.94 | 2021-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $384.42 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Lilly USA, LLC | $317.72 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $314.07 | 2021-2025 | Fasenra, Airsupra, Farxiga |
| Abbott Laboratories | $100.10 | 2022-2024 | Freestyle Libre 3 |
| Pfizer INC. | $90.94 | 2024-2025 | |
| Astellas Pharma US INC | $65.99 | 2024 | |
| Vanda Pharmaceuticals INC. | $60.60 | 2025 | Fanapt |
| Phathom Pharmaceuticals, INC. | $56.98 | 2024 | Voquezna |
| Dexcom, INC. | $46.14 | 2024-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $35.81 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.25 | 2024-2025 | Jardiance |
| Amgen INC. | $32.86 | 2025 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.47 | 2025 | Xifaxan |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $21.40 | 2024 | |
| Sanofi-Aventis U.S. LLC | $18.13 | 2021 | |
| Exact Sciences Corporation | $17.85 | 2023 | Cologuard Collection Kit |
| Organon LLC | $17.27 | 2024 | |
| Glaxosmithkline, LLC. | $16.81 | 2025 | Bexsero, Penmenvy |
| Kowa Pharmaceuticals America, INC. | $14.22 | 2025 | Zoryve |
| Galderma Laboratories, L.P. | $13.91 | 2024 | Dysport |
| Idorsia Pharmaceuticals US INC | $13.64 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jada Kitchen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.